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ABSTRACT
JENNIFER LYNNE WATSON
CHANGING DESTINIES:
AN OVERVIEW OF THE HUMAN GENOME PROJECT
1999
DR. RICHARD J. MEAGHER
MASTER OF ARTS IN HIGHER EDUCATION

The Human Genome Project was initiated in 1988. Its purpose being to sequence the
entire human genome, including the noncoding regions by 2005. Through the research
conduced, due to the project, several genes associated with specific diseases have been
identified. This paper is a review of the Human Genome Project and genes that have been
associated with the onset of specific disease.

Cystic Fibrosis, a disease affecting the

respiratory system, has been isolated to a gene on chromosome 7. Alzheimer's Disease, the
disease which is most responsible for dementia, has several genes associated with its onset.
These genes lie on chromosomes 21, 19, 14 and 1. Two genes have been associated with
Breast Cancer, Breast Cancer I (BRCAI), found on chromosome 17, and Breast Cancer 2
(BRCA 2), found on chromosome 13. A gene found on chromosome 4 is responsible for the
onset of Huntington Disease, a disease that causes neural cell death. Although the gene
responsible for Schizophrenia is not yet clear, there has been some speculation that
chromosome 22 may be involved with its onset; however, there is still additional research that
needs to be conducted. Through the information that has been discovered by genomic

research, new treatment strategies are being developed to treat these diseases and hopefully
someday defeat them.

MINI-ABSTRACT
JENNIFER LYNNE WATSON
CHANGING DESTINIES:
AN OVERVIEW OF THE HUMAN GENOME PROJECT
1999
DR. RICHARD J. MEAGHER
MASTER OF ARTS IN HIGHER EDUCATION

The Human Genome Project was developed to sequence the entire human genome and
identify diseases associated with specific genes. This paper is a review of the Human Genome
Project and the genes that have been associated with five specific diseases: Cystic Fibrosis,
Alzheimer's Disease, Breast Cancer, Huntington Disease and Schizophrenia.
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INTRODUCTION
Over the centuries, man has been striving to unravel the mysteries of the human body.
Through the advancement of science and technology what was once misunderstood is now
considered common knowledge. From the original observation of cells to the discovery of
the molecular structure of deoxyribose nucleic acid (DNA), scientists have challenged their
own abilities to discover the truth about life. As more information about DNA became
known, its influence on man's destiny was apparent. The challenge of trying to unravel the
genetic code was set before scientists. If the code that makes us who we are could be
deciphered, then problems within the code that lead to disease could be identified and possibly
treated or altered. This ambitious undertaking is what is known today as the Human Genome
Project.
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LITERATURE REVIEW
The Human Genome Project is a research project that is being conducted on an
international level. The purpose of this research is to construct both genetic and physical
maps of the estimated 50,000 to 100,000 genes, which make up the human genome, with an
original deadline of 2005 (Lyon and Gorner, 1995). In addition to the mapping of human
genes, scientists are striving to sequence the 3 billion nucleotide pairs of the human genome,
including all of the non-coding regions (Marshall, 1996). This complex map of the human
genome will provide information that is needed to understand human biology and disease on
a genetic level (Collins, et al., 1995). Once specific genes are identified and linked to specific
diseases, they can be examined through biological experimentation and new medical
treatments can be initiated (Marshall, 1996). This research will help in the understanding of
over 4000 genetic diseases that plague mankind, as well as many diseases in which genetic
predisposition plays a role. (National Human Genome Research Institute, 1998).
In the summer of 1985, the prospect of researching the human genome was first
discussed seriously. Nobelist, Renato Dulbecco, former president of the Salk Institute,
described two ways to combat the killers of the twentieth century, "Either to try to discover
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the genes involved in malignancy by a piecemeal approach, or to sequence the whole genome
of a selected species". Dulbecco encouraged the United States to initiate the search for the
total sequence of the human genome and to do it with the same vigor that was used to
'conquer space'. Coincidentally, during the time when Dulbecco was pressing for the
initiation of this research the Department of Energy was searching for new projects to fund.
The Department of Energy did a great deal of research on this topic and ultimately Congress
approved a fifteen-year project. The project had a funding potential of $200 million per year,
$3 billion total ($1 per nucleotide sequence). Thus, the Human Genome Project was initiated
and proclaimed the 'Holy Grail' of biology (Lyon and Gorner, 1995).
The initial United States involvement stemmed from the National Institute of Health.
The director of the National Institute of Health, James Wyngaarden, created the National
Center for Human Genome Research in October 1988. James Watson was asked, and agreed,
to head the center. Watson, also the director of the Cold Spring Harbor Laboratory,
embraced the challenge and stated that, "We used to think our future was in the stars, now
we know it is in our genes". (Lyon and Gorner, 1995).
In accordance with Watson and legislation by Congress, the Human Genome Project
consisted of four tiers which included: mapping the twenty three human chromosomes,
sequencing these chromosomes in their entirety including the non-coding sequences, placing
this information on computer databases and allowing scientists throughout the world to have
access to the information, and finally, initiating an ethical component to the project so that
the knowledge obtained is not used in any aspect of discrimination (Lyon and Gorner, 1995).
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In the Fall of 1991, as the Human Genome Project continued progressing, James
Watson found himself on unsettled ground. Bernadine Healy, Wyngaarden's successor, made
it clear, at least in Watson's perception, that she wanted him to step down from the post due
to conflicts of interest concerning the project.

In April 1992 Watson quit, faxing his

resignation to Healy (Lyon and Gorner, 1995).
The National Institute of Health did not replace Watson for almost a year, and many
"insiders" doubted that Healy and her staff would be able to find a person adequate enough
to fill Watson's shoes. In the fall of 1992 the announcement was made that Francis Collins,
a universally respected scientist, was offered the position. In April 1993 Collins assumed
command of the project (Lyon and Gorner, 1995).
Observations about the progress of the Human Genome Project in its first five years
were made by Collins and Galas (1993).

The first observation they made focused on

technology. The continuing development of successful technological approaches that can be
used in genomic and genetic research has been a contributing factor to the programs initial
success, and will be a critical component in the future of the project. The second observation
they made involved the level at which genomic research was being focused. Initially, a great
deal of time was spent on Large-scale mapping which focused on the construction of
chromosomal maps. Genetic maps and physical maps have been constructed using the
information gathered from the Large-scale mapping efforts. However, other information
gathered with the use of Small-scale mapping, as well as Large-scale mapping, will be useful
for further study of the human genome. The third and final observation was that the
identification of genes with the use of maps and sequences, which was an original goal of the
4

project, has developed into a definite activity of the project. The progress that has been made
in the area of gene identification, along with new technology that has been developed for
gene identification, will help with the production of more detailed maps (Collins and Galas,
1993).
Collins and Galas (1993) also modified the original five year plan for the Human
Genome Project stating new goals that they hoped would be achieved in the next five years
of the project. These goals were divided into separate categories, the first of which deals with
"The Genetic Map". The five year goal is to complete a human genetic map that is fully
connected and contains 'markers' that are on average spaced 2 to 5 centimorgans apart. A
centimorgan (cM) is roughly one million base pairs. A genetic map is made by determining
how often two 'markers' are inherited together. A 'marker' can be a physical trait, a specific
medical condition or syndrome, or a DNA sequence that is detectable (The National Human
Genome Research Institute, 1998). Rowen (1997) states that with the use of various
techniques 'markers' have been placed across the genome every 200 kb on average. The use
of genetic maps along with "florescence in-situ hybridization" and "radiation hybrid mapping"
are techniques that have been used to locate 'markers' (Rowen, 1997).
The second goal stated by Collins and Galas (1993) deals with the creation of "The
Physical Map". They hoped to complete an "STS-based physical map of the human genome
with a resolution of 100 kb". STS refers to a "sequence-tagged site" which The National
Human Genome Research Institute (1998) describes as a short DNA sequence that, through
research, has been categorized as unique. In the past, it has been difficult for researchers to
compare the results of physical maps generated by their colleagues because there were several
5

different mapping methods that were being used to generate physical maps. Initiating the
STS technique will give researchers one common "language" to report their findings in, no
matter what type of method they use. The idea behind this system is that each mapped
element is represented by an STS and the order and spacing of the STS's are also shown.
Rowen (1997) reports that by using this STS system researchers have been able to assemble
a physical map for most of the human genome.
The third goal described by Collins and Galas (1993) involves DNA sequencing. New
technology and improvements on current methods of sequencing are goals of the Human
Genome Project in order to lower the cost of sequencing to $. 50 per nucleotide. Other goals
include developing technology in order to conduct "high throughput" sequencing, as well as
sequencing a total amount of 50 Megabases (Mb) per year. In reality, the productivity of the
researchers involved in sequencing the human genome has been very low. The director of the
Human Sequencing Program, Mark Adams, at The Institute of Genomic Research in
Rockville, Maryland, does not seem to think they will be able to achieve their stated goal of
sequencing 100 Mb per year by 1999 or 2000. The Whitehead Institute of Biomedical
Research in Cambridge, Massachusetts, expected to have completed 23 million bases by May
1998, and have actually completed less that 9 million. Similarly, The Genome Center at
Baylor College of Medicine in Houston, Texas, had an original goal of having 15 million base
pairs to submit to Genbank, a public database that contains sequencing data, but only
submitted 8 million bases instead (Pennisi, 1998). Koonin (1998) states that less than 5% of
the human genome has been sequenced. The traditional method used for sequencing DNA,
called Sanger sequencing, involves using DNA precursors that are radioactively labeled with
6

32P. The DNA fragments are separated according to their length using polyacrylamide gel
electrophoresis. The results of the DNA sequencing are determined by autoradiography
(Russell, 1992). Koonin (1998) states specific disadvantages of using the present technology
for DNA sequencing. These drawbacks include the time and labor that is involved in
preparing and running polyacrylamide gels, as well as the large amount of samples that are
needed to obtain good results. According to Pennisi (1989), The National Human Genome
Research Institute has funded six pilot centers giving them free reign to choose any strategy
for sequencing that they prefer. There were only a few rules that these centers had to follow.
The most important one being that the final data they presented had to be 99.99% accurate,
that is to say, there could only be one error for every 10,000 bases they sequenced. The
ultimate challenge presented to the centers is to be able to keep their standards high without
having a significant increase in the cost of productivity. Ultimately, improvements on
existing techniques, and development of new techniques based on increased technology and
principles, will help in creating a complete sequence of the human genome (Pennisi, 1998).
"Gene Identification" is another goal of the Human Genome Project. Collins' and
Galas' (1993) goals for gene identification include identifying genes using more proficient
methods, as well as placing the genes that have been identified on physical maps. Since the
inception of the Human Genome Project, the availability of genetic and physical maps of the
human genome, and also of the genomes of certain model organisms, have increased. Using
these genetic maps and physical maps that have been constructed as a result of the Human
Genome Project has helped in the discovery of genes that underlie Mendelian disorders
(Collins et. al., 1997).
7

"Technology Development" is an important component of the Human Genome
project. The goal in the area of technology development is to expand the current technology
for all aspects the Human Genome Project, such as DNA sequencing, mapping, and gene
identification (Collins and Galas, 1993). Specific types of technology, such as robotics, have
been experimented with. Eric Lander, head of the Whitehead Center at MIT, estimated a
30%-40% savings in labor costs with the use of robots. Later Lander realized that this
estimate was "over optimistic" (Pennisi, 1998). The original plan that was established by
Watson aimed to develop technologies and refine them by sequencing the genome of simpler
organisms. This strategy did work in that when the Human Genome Project began, Watson
estimated that to sequence one base pair the cost was approximately $10 with a potential to
be reduced to $1 per base pair within 5 years (Marwick, 1989).
The next set of goals that Collins and Galas (1993) focused on were those associated
with "Model Organisms". A great deal of progress has been made with respect to model
organisms which are being researched in conjunction with the human genome. The original
goals that were set in this area are expected to be reached and possibly even surpassed. The
revised goals include completing an "STS map of the mouse at 300 kb resolution". In
addition to the mouse genome, the goals include completing the sequence of the Escherichia
coli and Saccharomyces cerevisiae genome.
The continued development of new databases and database tools for storage and
retrieval of information gathered during the course of the Human Genome Project is an
ongoing goal. Specifically, Collins and Galas (1993) have goals in the area of "informatics"
to create databases that have easy access, as well as information exchange among databases.
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In addition, they would like to see the consolidation of software, as well as offering tools that
will allow for comparing genome information from one database to another (Collins and
Galas, 1993). The three databases that are of essential importance to the Human Genome
Project are GenBank, Genome Data Bank, and Protein Information Resources.

The

information they provide consists of DNA sequences (GenBank), chromosome mapping
information (Genome Data Base), and protein sequence and structure (Protein Information
Resources). The Department of Energy and The National Institute of Health established a
Joint Informatics Task Force (JITF) to help in the development of "detailed informatics
programs" (The National Human Genome Research Institute (1998).
There has also been modifications made in the area of the "Ethical, Legal and Social
Implications" of the Human Genome Project. In October 1988, when James Watson officially
announced his intentions for initiating the Human Genome Project, one of the first questions
that he was asked was about the social implications of this research. In response to this issue
there was a committee formed, the National Center for Human Genome Researcher's
Committee on Ethical, Legal and Social Implications (ELSI) which received 5% of the budget
designated for human genome research (Marshall, 1996). The initiation of this committee
established the largest biomedical ethics program in this country and possibly the largest in
the world (Zylke, 1992). This research would address issues such as genetic discrimination,
genetic elitism, and issues of eugenics. With the increasing amount of information that has
been gathered since the inception of the Human Genome Project, the goals for the ELSI
component of the project have been modified. One of the goals is to develop policies
involving services with regard to genetic testing. Another goal of the ELSI is to reduce
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genetic discrimination allowing for greater acceptance to genetic variability. In addition, there
is a goal to increase public, as well as professional education to the issues that are raised by
researching the human genome (Collins and Galas, 1993).
The last three categories Collins and Galas (1993) have discussed are in the areas of
"Training", 'Technology Transfer" and "Outreach". The goal that they have established for
training is to encourage scientists that are involved in various fields of study, related to the
Human Genome Project, to become familiar with the techniques used in genome research.
The goal of technology transfer is to encourage transfer of information within and between
various genome centers. Finally, the goals concerning outreach include sharing information
within 6 months of its discovery by way of a public database, and the development of
"distribution centers" that would process and circulate information about the Human Genome
Project (Collins and Galas, 1993).
Since the inception of the Human Genome Project, it has been a federally funded
program with the most substantial portion of the budget provided by The National Institute
of Health and The Department of Energy (Lyon and Gorner, 1995,). Recently, J. Craig
Venter, former researcher at The National Institute of Health, (Lyon and Gorner, 1995) and
Perkin-Elmer Corporation have teamed up to create a new company, The Institute of
Genomic Research (TIGR). The goal of this private company is to sequence the human
genome in three years with a cost of $200 million to $300 million (Travis, 1998). The
technique that Venter is using is referred to as "shotgun sequencing". This technique involves
"randomly breaking DNA into segments of various sizes and cloning these fragments into
vectors". 'This project aims to produce a highly accurate, ordered sequence that spans more
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than 99.9% of the human genome" (Venter et, al., 1998). The shotgun approach to
sequencing does not include any mapping as does the Human Genome Project. Instead, it
enlists the help of a computer to sort through and "line up" the thousands of DNA sequences
that it is presented with. This strategy will result in a sequence that is not complete, leaving
3,000 to 4,000 gaps in the finished product, each gap consisting of approximately 50 base
pairs each. Venter et. al. (1998) proposes that the regions that will be left are areas that
consist of"repetitive DNA" which is of little interest. Venter et.al. (1998) also supports the
fact that the genome sequence his company constructs will be just as accurate as its
competitors. (Travis, 1998).

The establishment of this new company has sparked the leaders

of the Human Genome Project to change the deadlines they have set for the completion of the
project. They now plan to have a completed sequence of the human genome by 2003 with
a "working draft" available by 2001. Francis Collins, director of the National Human Genome

Research Institute, states that increasing the productivity of DNA sequencing "eclipses all
other priorities" (Holden, 1998).
Although a complete sequence of the human genome has not been constructed thus
far, there has still been a great deal of progress made in the area of gene identification and the
involvement of these genes in the area of medical genetics. In this paper five different
disorders will be examined: Cystic fibrosis, Alzheimer's disease, Breast cancer, Huntington
disease and Schizophrenia. The information presented will include what discoveries have
been made on a genetic level about these disorders, the biochemistry of the genes involved
in these disorders, and also innovative therapies that are being conducted to help in the
prevention and treatment of these disorders.
II

MATERIALS AND METHODS
Cystic Fibrosis, Alzheimer's Disease, Breast Cancer, Huntington Disease and
Schizophrenia all have genes that have been associated with their onset. In this paper each
disease will be examined. The genes that influence the onset of these diseases will also be
discussed. Included in the discussion will be the strategies that were employed to isolate
these specific genes. In some cases the function of specific genes have been identified. These
functions will be incorporated in the analysis of the disease. Also, in some cases, various
treatment strategies have been developed to combat the inevitable fate that these genes lead
to.
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CHAPTER 1: CYSTIC FIBROSIS
In August 1989, Francis Collins and a group of his scientific colleagues were rushed
to Washington D.C. to attend several press conferences. The reason for these meetings was
to announce that they had identified the gene and the protein defect which results in the
devastating disease Cystic Fibrosis (CF). This announcement thrilled thousands, especially
parents of CF victims. The discovery of this gene would make it possible to develop drug
therapies that would treat the problem at the source, not just the symptoms (Lyon and
Gorner, 1995).
Cystic Fibrosis, regarded as the most commonly occurring autosomal disease in the
Caucasian population, has a frequency of I in 2000 live births and a carrier population of
about 5%. Clinically, the major symptom of CF is the obstruction of airways by thick mucus
that is very sticky. This results in respiratory tract infections (Collins, 1992). "Chronic
pulmonary disease, pancreatic exocrine insufficiency, and an increased concentration of sweat
electrolytes" are also common symptoms of the disease (Rommens et al., 1989). A common
method for the management of cystic fibrosis is chest percussion which helps to clear infected
mucus secretions from the respiratory tract. A great deal of importance is also placed on the
13

nutritional habits of the patient. The chances for survival have increased over the past 4
decades. The average survival age is roughly 29 years (Collins, 1992).
Cystic Fibrosis has long been a mystery to physiologists and biochemists; however,
more recently they have been able to solve the riddle behind this disorder. In patients with
CF the mechanism that controls the efflux of chloride ions across the apical membrane does
not function properly. There is an elevation of adenosine 3',5'-monophosphate (cyclic AMP),
and cyclic AMP-dependent kinase (PKA) is activated by cyclic AMP in CF cells, but PKA
fails to activate a chloride conductance. This information was new to CF researchers, but was
not sufficient to identify the protein product of the gene that is defective in CF patients
(Collins, 1992). A more aggressive strategy was employed to identify the CF gene, positional
cloning, which was triumphant in the identification of the CF gene (Collins, 1992). The
introductory stages of this process included the mapping of the CF gene to chromosome 7.
This was achieved by examining DNA from affected individuals, as well as a panel of
polymorphic DNA markers through linkage analysis. Through this process the CF locus was
unambiguously assigned to the long arm of chromosome 7, band q3 1. The identification of
MET and D7S8, closely linked flanking markers, made it possible to pinpoint the CF gene.
The gene cloning strategies employed included chromosome jumping from flanking markers,
and pulse field gel electrophoresis to clone DNA fragments from defined physical regions.
"Chromosome microdissection" and saturation cloning of a large number of DNA markers
from the q31 region were also used. Saturation mapping was used to identify two DNA
markers, D7S122 and D7S340.

These two markers, along with MET and D7S8, helped to

create genetic and physical maps of the CF locus. Their order on the CF locus are as follows:
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MET-D7S340-D7S 122-D7S8 with intervals of 500-10-98 Kilo-Base (kb) respectively. As
indicated by the genetic data, D7S122 and D7S340 are in close proximity on the CF locus.
Next, a large portion of the DNA surrounding these markers needed to be cloned to seek out
candidate gene sequences. Through the use of chromosome 'walking' and 'jumping'
techniques, ten genomic libraries were constructed, as well as a restriction map of the cloned
human DNA (Rommens et al., 1989).
The entire cloned region of the CF locus extended over 500 kb. To ensure that the
DNA segment isolated by the chromosome 'walking' and 'jumping' techniques was collinear
with the genomic sequence, each segment was examined using the following techniques:
"Hybridization analysis with human-rodent somatic hybrid cell lines to confirm localization
on chromosome 7, pulse field gel electrophoresis, and comparison of the restriction map of
the cloned DNA to that of the genomic DNA." The evaluations indicated that most phage
and cosmid isolated DNA segments were correct, although a few inconsistencies resulted
from cloning artifacts, as well as cross-hybridizing sequences that are found in other areas of
the human genome (Rommens et al., 1989).
Through the use of long range restriction mapping it was indicated that the entire CF
locus was contained on a 380 kb Sal I fragment. The restriction sites derived, from the pulse
field gel electrophoresis analysis, were aligned with overlapping genomic codes to indicate
that the CF locus was actually about 250 kb (Rommens et al., 1989) with a messenger RNA
(mRNA) reduced to approximately 6.5 kb. This mRNA encode for a protein containing 1480
amino acids (Collins ,1992).
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The final proof that was needed to confirm that the CF gene was identified was the
mutation that distinguished normal individuals from affected individuals. This was done by
comparing cDNA sequences acquired from CF and unaffected (N) individuals.. The most
apparent difference between the CF and N sequences was a 3 Base-Pair (bp) deletion in Exon
10 of the candidate gene (Collins, 1992). This deletion results in the loss of the amino acid
phenylalanine (AF508) in the CF polypeptide that was predicted. Kerem et al. (1989) studied
the proportion of CF patients carrying this deletion (AF508). Genomic DNA samples were
taken from patients and their parents. These samples were amplified by PCR and hybridized
to 32P labeled oligonucleotides specific for the normal and mutant sequences. The results of
their study indicated that about 68% of the CF chromosomes in the patient population had
the A508 mutation. Conversely, none of the N chromosomes had the deletion. The results
that they obtained suggested that this 3 bp deletion is specific to CF and is the major mutation
which results in the disease (Kerem et al., 1989). Presently, there are over 170 mutations that
have been described in the CF gene, many of these mutations have only been identified in a
single individual (Collins, 1992).
Now that the CF gene had been identified, it was necessary to find the protein that it
codes for. Lyon and Gomer (1995) state that the CF gene codes for a protein which consists
of 1479 amino acids, and the N gene codes for a protein consisting of 1480 amino acids. The
absence of the 3 bp sequence results in a loss of the amino acid phenylalanine. Researchers
named this protein CFTR, the cystic fibrosis transmembrane conductance regulator (Lyon and
Gorner, 1995). With regard to genetic data and predicted properties, it is feasible to resolve
that CFTR is responsible for CF (Riordan et al., 1989).
16

The amino acid sequence of CFTR is very similar to a family of proteins which are
involved in active transport of substances across cell membranes. These proteins can be
found in a wide range of species, from bacteria to mammals. The subfamily these proteins
belong to is called the traffic adenosine triphosphatase family (ATPase).

They have a

common characteristic in that they have one or two hydrophobic transmembrane domains.
They also have one or two nucleotide binding folds (NBFs) which binds, as well as cleaves,
ATP. This provides the energy resource for transport. CFTR was placed in this subfamily
because it has two transmembrane domains and two NBFs. Another characteristic of CFTR
is its highly charged central domain. This domain contains serine residues which are thought
to be targets of PKA-mediated phosphorylation (Collins, 1992).
The mystery of CF was beginning to unravel; however, to most researchers, the most
elusive characteristic of CF was how one genetic flaw could produce such diverse symptoms.
Interestingly, some researchers discovered that the cells that line the respiratory tract in CF
patients cannot transport chloride ions across the cell to the outside. This affects CF patients
by trapping water inside the cell making it impossible to dilute the mucus in their respiratory
tract; therefore, the mucus remains thick (Lyon and Gorner, 1995).
Through further studies and experimentation it was concluded that CFTR is a chloride
channel instead of the initially speculated active transport mechanism (Collins, 1992). The
structure of the protein is similar to that of a family of proteins which act as channels (Lyon
and Gorner, 1995). Riordan et al. (1989) suggests another possibility, the CFTR may not be
an ion channel, but may regulate the activities of an ion channel. In either situation, the fact
that the ATP-binding domain is present on CFTR implies that the hydrolysis of ATP is
17

necessary for transport functions. The A508 may result in the improper binding of ATP
resulting in an ineffective transport of ions. Bradbury et al. (1992) confirmed that the CFTR
protein does not function properly in patients with CF, and that the N CFTR gene works as
a chloride ion channel.

They state that "CFTR can function as a cyclicAMP-activated

chloride channel within epithelial cells, where it regulates plasma membrane chloride
conductance."
The research that has been conducted thus far to unravel the mystery of CF has
initiated the development of new methods of treatment, such as aerosol therapy, as well as
new ways to identify and treat the disease through neonatal screening. In the area of aerosol
therapy, recombinant human deoxyribonuclease I (rhDNase) has been used to treat CF. The
rhDNase is administered by aerosol and acts in-vivo by attaching to high-molecular-weight
DNA to increase the elimination of mucus, and may be a possibility for the short-term
management of lung function for CF patients (Hubband et al., 1992). In addition, adenovirus
vectors have been developed to fight CF. Adenoviruses have many unique qualities that make
them desirable, such as being able to infect cells in any phase, unlike retroviruses. This
characteristic is essential to the lungs because the number of cells going through division at
any one time is relatively low. In this procedure N CFTR genes are administered by aerosol
into the CF patients lungs in the form of an adenovirus. The N CFTR combines with the CF
CFTR allowing the cells chloride ion channels to function normally improving airway function
( Lyon and Gomer, 1995). Collins (1992) points out that this treatment may be transitory and
treatments may need to be repeated often.
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There has also been success in the area of Neonatal Screening. This screening has
been used to enhance the early diagnosis of CF neonatally, as well as offer early treatment
options to the parents. Through CF screening, mothers have been able to change their
nutritional habits to improve the health of the baby. The CF screening also allows the family
to prepare for the arrival of a child with CF and to help them plan for the best medical
treatments possible.

The infants who were screened and treated neonatally had less

pulmonary inflammation and less deterioration of lung function. These infants suffered no
long-term adverse affects due to the screening program. This should be encouraging for
families who are deciding if they want to go through the CF screening process (DankertRoelse and Meerman, 1997).
There are many advances that have been made to help fight CF. The research that has
been done and the new treatments that are being employed are helping families cope, and also
giving them new hope to fight this terrible disease.
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CHAPTER 2: ALZHEIMER'S DISEASE
Alzheimer's disease, the disease which is most responsible for dementia, was initially
described in 1906 by Alois Alzheimer, a German physician. Through the use of autopsy
techniques employed at the time Alzheimer discovered that the cerebral cortex of a 55-yearold woman, who had suffered from dementia, had nerve cell abnormalities.

These

abnormalities consisted of tangled fibers and clusters of degenerated nerve endings, or plaques
(Check, 1989). These two abnormalities described by Alzheimer are seen in most deceased
Alzheimer's disease victims and are today described as hallmarks of the disease (Lyon and
Gorner, 1995).
Plaques, which are developed at the end of nerve cells, result in the blunting of the
tips of the 'branch like spines', which are known as axons and dendrites. The nerve cells
communicate

through these

axons and dendrites by chemicals referred to as

neurotransmitters. It is known today that plaques consist of a tough fibrous protein, Bamyloid, surrounding either dead or dying nerve tissue. Tangles, the other abnormality
described by Alzheimer, are filaments within the nerve cells that are twisted or frayed, similar
to a wire that has been 'burnt out' (Lyon and Gorner, 1995).
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Plaques and tangles are found prominently in the cells of the cortex and hippocampus,
which are the two major areas of the brain associated with speech, memory, and reasoning.
However, it is not known whether plaques and tangles are what causes Alzheimer's disease,
or if they are merely an effect (Lyon and Gorner, 1995).
In addition to plaques and tangles, Alzheimer's disease patients produce less
acetylcholine, a neurotransmitter found in the brain. This neurotransmitter is made in the
basal nucleus, a brain structure, and is disbursed to the cortex and hippocampus. The degree
to which Alzheimer's disease victims lack acetylcholine is directly related to the severity of
memory loss they experience.

In addition to acetylcholine, other neurotransmitters,

somatostatin, noradrenaline, and serotonin, are not produced in normal amounts in
Alzheimer's disease patients.

Presently, the lack of specific neurotransmitters is a

consequence of Alzheimer's disease, rather than a cause (Lyon and Gorner, 1995). So then,
what is the cause of Alzheimer's disease?
There have been many theories as to the cause of Alzheimer's disease, including a
viral cause which suggests that a viral infection in the brain causes selective brain cells to die.
Another hypothesis suggests that a toxic accumulation of aluminum in the brain may cause
Alzheimer's disease. This suggestion was made because Alzheimer's disease patients had a
higher than normal concentration of aluminum salts in their brain tissue (Lyon and Gomer,
1995). An additional theory which hypothesizes genetic causes for Alzheimer's disease is
presently the most active area of research that is being pursued (Check, 1989).
In some instances Alzheimer's disease affects more than one person in a family. It has
been suggested that this form of Alzheimer's disease, familial Alzheimer's disease, is caused
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by a genetic defect (St George-Hyslop et al., 1987). In a report published by St GeorgeHyslop et al. (1987) the chromosomal location of a defective gene contributing to
Alzheimer's disease was announced. The focus of their study was on chromosome 21. The
rational for this being that a large number of Down's Syndrome (trisomy 21) patients who
reached older age developed "Alzheimer-like neuropathologic changes." Their hypothesis
was that a gene on chromosome 21 could influence the development of Alzheimer's disease.
In their study, St. George-Hyslop et al. (1987), used genetic linkage of polymorphic
DNA markers to find the chromosomal location of familial Alzheimer's disease. Through
their study it was shown that the familial Alzheimer's disease gene does lie on chromosome
21 in the region of 21ql 1.2-21q21. Several DNA markers were used to try to pinpoint the
location of familial Alzheimer's disease on chromosome 21. The data was statistically
analyzed using the logarithm of likelihood of linkage (lod score) to familial Alzheimer's
disease. Two markers, D21SI/D21SIS

, gave positive lod scores for the location of a familial

Alzheimer's disease allele on chromosome 21 suggesting that the gene is located in the area
of these two markers. St. George-Hyslop et al's (1987) study also confirmed that the familial
Alzheimer's disease gene is not situated on the Down's Syndrome region (21q22) of
chromosome 21.

Rather, it is just outside the region falling between 2lql 1.2-21q21. In

addition, St. George-Hyslop et al. (1987) also suggested that the familial Alzheimer's disease
gene found on chromosome 21 is associated primarily with early-onset (30 to 60 years)
familial Alzheimer's disease.

Although St. George-Hyslop et al. (1987) reportedly located

the cite of familial Alzheimer's disease on chromosome 21, these findings were not initially
confirmed by other researchers. It was suggested then that familial Alzheimer's disease could
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be genetically heterogeneous, and chromosome 21 may be responsible for only a subset of
familial Alzheimer's disease cases (Schellenberg et al. 1991).
Schellenberg et al. (1991) conducted a study to support St. George-Hyslop et al's.
(1987) findings. This study was designed to test the genetic linkage of familial Alzheimer's
disease in 48 families. The families included in the study had 2 or more generations with
either early-onset or late-onset (60 years or older) Alzheimer's disease. Also involved in the
study were 7 Volga German families whose ancestors were immigrants from the Hesse region
of Germany to Russia in the 1760's. These families then moved to the United States in late
1800's.

This subset of families is thought to be genetically homogeneous for familial

Alzheimer's disease. In their study Schellenberg et al. (1991) used several DNA markers
including D21S16, D21S13, D21S II0, and D21S1/S11. These markers were used to test
for genetic linkage to the 21ql l-q21 region of chromosome 21.

The results that they

obtained from their study indicated that as a sum the families did not show genetic linkage to
21 q l1.2-q21; however, some subsets of kindred did show genetic linkage to 21 q ll-q21.
Schellenberg et al. (1991) analyzed the results of the late-onset kindred, their research
indicated negative lod scores for all of the DNA markers used in the study. Early-onset nonVolga Germans were then analyzed as a subgroup, the lod scores for D21S13 and D21S16
markers were positive in some families. This data supports St. George-Hyslop et al's (1987)
hypothesis that early-onset familial Alzheimer's disease is linked to 21ql1l-q21. The Volga
German families showed congruous negative results for linkage to the 21ql1-q21 region,
supporting the hypothesis that the familial Alzheimer's disease locus for these kindred is not
located on chromosome 21ql 1-q21 (Schellenberg, et al., 1991). Their research also supports
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the hypothesis that 21 q 1 -q21 may be responsible for only a subset of familial Alzheimer's
disease cases (Schellenberg et al., 1991).
Interestingly, the kindred who show genetic linkage to chromosome 21 also have a
point mutation in the B-Amyloid Precursor Protein (APP) gene. This gene is very close to
the area on chromosome 21 where linkage to the familial Alzheimer's disease gene has been
demonstrated (Goate et al., 1991). In their study Goate et al. (1991) analyzed the APP gene,
beginning with the sequencing of exon 17, which indicated a cytosine to thiamine transition
at base pair 1249. This transition causes a change in the amino acid 717 from valine to
isoleucine. Chartier-Harlin (1991) reported a thymine to guanine transition at base pair 2150
which results in an amino acid change from valine to glycine at codon 717. In addition to the
valine to isoleucine and valine to glycine shifts, there is also a valine to phenylalanine shift at
codon 717. These missense mutations have been linked to some cases of early- onset
Alzheimer's disease (Tanzi et al. 1992). Since these mutations all occur at the same codon,
Chartier-Harlin et al. (1991) surmise that this could be a coincidence, although it is unlikely.
The substitution of valine with isoleucine, glycine, and phenylalanine increase the amount of
B-amyloid protein that is deposited due to a change in the APP processing, but the mechanism
for deposition is not yet known (Citron et al., 1992).
It seems evident that the APP gene located on chromosome 21 has a vital role in
familial Alzheimer's disease, but accounts for less than 1% of all Alzheimer's disease cases.
Therefore, additional research needed to be conducted to exploit other chromosomes involved
with familial Alzheimer's disease (Lyon & Gorner, 1995).
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Researchers focused their attention on chromosome 19, linking the disorder to a
specific gene, apolipoprotein E (APOE), located on chromosome 19q 13.2. The APOE locus
has 4 alleles: APOE 2, APOE 3, and APOE4 . People who have the APOE 4 allele seem to have
an increased risk of Alzheimer's disease (Lyon & Gorner, 1995). As reported by Corder et
al. (1993), 80% of familial and 64% of sporadic late onset Alzheimer's disease victims have
at least one APOE 4 . These statistics implicate APOE 4 as the cause of more than one half of
all Alzheimer's disease cases. Corder et al. (1993) suggest that an increase in the gene dose
of APOE 4 increases one's risk for Alzheimer's disease and also results in an earlier onset.
The presence of each additional APOE4 results in an increase risk of Alzheimer's disease by
a "factor of 2.84". In contrast, Lyon and Gorner (1995) state that the APOE 4 gene is not
responsible for Alzheimer's disease directly; rather, it is the lack of APOE3 and APOE2 that
increase a persons vulnerability to Alzheimer's disease. This suggests that APOE2 and
APOE 3 have some protective factors. It is not clear what involvement APQE as in the
nosogenesis of Alzheimer's disease; however, the protein, apoE isoform E, that is encoded
by APOE4 was found to be immunoreactive in plaques as well as tangles of Alzheimer's
disease patients. These findings, as well as statistical analysis, suggest that APOE 4 is directly
involved with Alzheimer's disease (Corder et al., 1993).
In addition to chromosome 21 and 19, chromosome 14 seems to have an association
with familial Alzheimer's disease. In a study conducted by Schellenberg et al. (1992) genetic
linkage of familial Alzheimer's disease on chromosome 14 was tested. In their research,
Schellenberg et al. (1992) studied families consisting of 3 or more affected individuals
spanning two or more generations. Their kindred also had at least one family member who
25

had died and had confirmed Alzheimer's disease based on autopsy results. These families
were divided into three groups, Volga Germans, non Volga Germans, and Volga Germans
and non-Volga Germans combined. DNA markers D14S1, D14S43, and D14S53 were tested
and lod scores were calculated. The D14S43 and D14S53 markers gave positive lod scores
for non-Volga German families. Conversely, the Volga German families showed negative lod
scores for all of the DNA markers used in the study. Through this study it was suggested that
an early-onset familial Alzheimer's disease locus was located on chromosome 14q24.3 and
could account for a large percentage of early-onset familial Alzheimer's disease (Sherrington
et al., 1992). Once the initial mapping of chromosome 14q24.3 was done the locus that was
detected near D14S43 and D14S53 markers was given the name AD3 locus. The AD3 locus
has been associated with an aggressive form of early-onset familial Alzheimer's disease.
Through linkage mapping, Sherrington et al. (1992) were able to define the regions containing
the AD3 gene and isolate approximately 19 transcripts that are encoded in this region. One
transcript, S182, is correspondent to a novel gene who's product is thought to consist of
'multiple transmembrane domains' and is reminiscent of an integral membrane protein. The
S182 transcript, which is 3.0kb, was sequenced revealing 5 different mutations which result
in the following amino acid changes: Methionine-leucine at codon 146; histidine-arginine
at codon 163; alanine-glutamic at codon 246; leucine-valine at codon 286; and finally
cysteine-tyrosine at codon 410. These mutations occur independently, but all seem to result
in early-onset familial Alzheimer's disease . Although there is strong evidence that the
mutations in S182 gene results in early-onset familial Alzheimer's disease Sherrington et al.
(1995) proposed two questions. First, what function does the gene have; secondly, "how do
26

these mutations confer a dominantly inherited familial Alzheimer's disease phenotype"?
Sherrington et al. (1995) suggest that the S182 protein is an integral membrane
protein, such as a receptor, a channel protein, or possibly a structural membrane protein. Its
function could possibly include the 'docking of other membrane bound proteins' or fusion
budding of membrane bound vesicles during protein transport. If the function of S182 is as
speculated, then the mutations found in S 182 could result in abnormal transport or processing
of APP, as well as aberrant interactions with cytoskeletal proteins. Although the functions
and processes of S 182 are not fully understood the fact that no mutations of S 182 are present
in normal controls indicates that it is highly probable that these missense mutations are
responsible for AD3 (Sherrington et al., 1995).
Through all of the research that has been conducted on familial Alzheimer's disease,
one group, the Volga German kindred, has shown consistent negative results as to genetic
linkage on chromosome 21, 14, and 19. Volga Germans, along with some families in which
familial Alzheimer's disease is inherited as an autosomal dominant trait, do not have a known
loci. Volga German are German immigrants in Russia that did not intermarry with the
surrounding population and remained culturally distinct. The average age of onset for
Alzheimer's disease in Volga Germans is 50.2 to 64.8 years of age (Levy-Lahad et al., 1995).
In a study conducted by Levy-Lahad (1995) chromosome 1 is explored for a possible
connection to familial Alzheimer's disease. DNA from 139 individuals of Volga German
kindred were prepared for study, 36 subjects had been clinically diagnosed with Alzheimer's
disease. A total of 21 DNA markers were used in the study, D I S279 had the most significant
lod score. Through further study it was discovered that the 112 bp allele was seen in the
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affected subjects compared to the controls. This data localized the familial Alzheimer's
disease locus to lq3 1-q42. Levy-Lahad et al's (1995) next strategy was to try to find the
mutations in the gene candidate for this locus. The first gene candidate which was tested
encodes cathepsin E. Cathepsin E is a protease that is found in the brains of Alzheimer's
disease patients in increased amounts. Interestingly, the second gene candidate that was
tested is a homolog to S182, which was a candidate gene in AD3. An expressed sequence
tagged of 475 bp was sequenced and compared to S182. This sequence, referred to as
T03796, is 80.5% identical to S182. T03796 is located between DIS439 and DIS479
markers on chromosome 1, this is consistent with their previous finding of a 112 bp allele
observed in affected kindred. The gene corresponding to the T03796 sequence, referred to
as the E5-1, gene was cloned and analyzed (Rogaev et al., 1995). In Levy-Lahad et al's
(1995) work the E5-1 gene is referred to as F (Full length)-T03796. The results indicate that
E5-1 has a 448 amino acid open reading frame that is homologous to S182. The E5-1 gene
was then analyzed for mutations, revealing two. The first mutation resulted from a adenineguanine substitution at nucleotide 1080 resulting in a methionine-valine change in codon 239.
Secondly, a change in nucleotide 787 from adenine to thymine was seen at codon 141, this
results in an amino acid change from asparagine to isoleucine. This second mutation is
referred to as N1411; interestingly, all of the subjects that had the N1411 mutations also had
the 112 bp allele. These mutations were not found in normal controls (Levy-Lahad et al.,
1995).
The predicted protein from E5-1 has seven transmembrane domains and is called
STM2 ("the second seven transmembrane gene associated with Alzheimer's disease"). The
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similarities between E5-1 and S182 are amazing, suggesting that the mutations in these genes
could possibly be negatively affecting the attachment or anchoring of their proteins into
membranes. Although the normal cellular function of E5-1 and S182 are not yet known, it
is possible that they have similar roles in cellular function and their mutations may hinder
normal cellular function (Levy-Lahad, 1995).
Rogaev et al. (1995) suggest that since the E5-1 and S182 genes are so similar,
sharing a 63% similar amino acid sequence, they may be members of a family of genes called
presenilins. According to Strooper et al. (1998) presenilins promote a "proteolytic activity
that cleaves the integral membrane domain of APP." When there is a mutation there is an
increased production of "amyloidogenic peptide amyloid" which results in the manifestation
of Alzheimer's disease.
The research that has been conducted on chromosomes 21, 19, 14 and 1 offers a
promising future for the detection and treatment of Alzheimer's disease. There are currently
few treatments for Alzheimer's disease. One possible treatment involves the use of nerve
growth factor (NGF), which is a protein involved in the growth of nerve cells (Lyon &
Gorner, 1995). In studies conducted in rats and monkeys NGF is injected into the brain. The
results indicate that nerve cell destruction in the "acetylcholine pathway of the basal nucleus
and hippocampus had been stopped." NGF stopped the shrinkage of nerve calls and also
promoted new connections between nerve cells (Lyon & Gorner, 1995).
Although the results seem positive, researchers are being cautious in the treatment of
Alzheimer's disease with NGF. The hypothesis is that NGF may make the disease worse,
specifically, it is thought that NGF may promote the growth of nerve cells, strangling the
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existing cells. The formation of new nerve cells could possibly lead to more B-Amyloid
deposition in the brain (Lyon & Gorner, 1995).
Although a great deal of progress has been made in understanding Alzheimer's
disease, its origin and processes, there is still much that remains a mystery. Hopefully there
will be a day when Alzheimer's disease is referred to as a disease of the past, not the present
and future, and the suffering will end for the victims of this disease as well as their families.
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CHAPTER 3: BREAST CANCER
Breast cancer is a common disease that affects 180,000 women per year and results
in approximately 50,000 deaths each year in the United States alone (Lyon and Gorner,
1995). The disease, which primarily affects women and is mostly sporadic, having no genetic
linkage, is estimated to develop in one out of eight women who live to the age of 95 (Miki
et al., 1994). Early detection is essential for proper medical management of the disease. If
breast cancer is diagnosed in more advanced stages, treatments may cause disfigurement or
not be successful at all. There is evidence that suggests that genetic factors do contribute to
a small percentage of the disease. Miki et al. (1994) estimate that approximately 5% of all
breast cancer cases are a result of genetic predisposition. These familial type cases of breast
cancer are thought to result from two different genes, BRCAI (Breast Cancer 1, located at
17ql2-q21) and BRCA2 (Breast Cancer 2, located at 13ql2-ql3), which result in
approximately 85% of all familial breast cancer cases. BRCAI has also been implicated in
some sporadic cases of breast cancer, as well as the early-onset of ovarian cancer (Korenberg
et al., 1995). Genetic predisposition results in a higher risk of developing the disease. The
percentage of risk for those inheritably susceptible to breast cancer are as follows: 37% by
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age 40, 66% by age 55, and an 82% risk over ones entire lifetime. In contrast, the risk of
developing breast cancer in non-genetically predisposed persons are as follows: .4% by age
40, 2.8% by age 50, and an 8.1% risk over an entire lifetime (Hall et al., 1990).
BRCA1 and BRCA2 both contribute to the early-onset (onset before 50 years of age)
of breast cancer. It is estimated that BRCA1 contributes to 45% of familial breast cancer,
leaving the other 55% as a result of BRCA2 and also some sporadic factors (Miki et al., 1994).
BRCA1 was first mapped to chromosome 17 by Hall et al. (1990). In their study a
total of 329 participants from 23 families were analyzed. In these families there were 146
reported cases of breast cancer. The families shared characteristics that are seen in familial
breast cancer cases including early-onset of the disease, and an increased number of men with
the disease. Hall et al. (1990) used various DNA markers in their study, including D17S74.
D17S74 had the highest lod score of all of the DNA markers and is located on chromosome
17q21. Additional research isolated BRCA1 to a 1 to 2 megabase region of chromosome 17.
Through further research BRCA1 was compressed further to a 600 kb region between
D17S1321 and D17S1325 markers (Miki et al., 1994).

Within the 600 kb region 65

candidate expression sequences were recognized, these expressed sequences were analyzed
through DNA sequencing. Through this process BRCA1 was narrowed down to a small area
in the 600 kb region previously mentioned and is associated with the DNA marker D17S855
(Miki et al., 1994). In the next stage of analysis cDNA of the full length of BRCA1 was
constructed, and upon evaluation one long open reading frame encoding a protein consisting
of 1863 amino acids and 22 exons was discovered (Miki et al., 1994). Also included in
BRCA1 are two zinc finger domains and an acidic COOH-terminal domain (Chen et al., 1995).
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The structure of BRCA1 was beginning to unravel, it was necessary to find specific
mutations in BRCA1 that may alter the function of the gene. Initial research by Futreal et al.
(1994) discussed three mutations found on the BRCA1 gene. The first mutation is glutamic
acid to Stop at nucleotide 1541, this stop codon creates a truncated protein which is missing
323 amino acids. The second and third mutations are missense mutations, alanine to glutamic
acid at nucleotide 1708 and methionine to arginine at nucleotide 1775. These mutations are
all absent in normal population controls. Interestingly, Futreal et al. (1994) did not discover
any sporadic mutations on BRCA1. They suggest that some mutations may have been missed
in the screening process or possibly some sporadic mutations are located in noncoding
sequences. Gayther et al. (1996) report that over 65 specific mutations have been detected
scattered throughout the BRCA1 gene with clusters of mutations in various areas. In their
study, Gayther et al. (1996) used a technique called multiplex heteroduplex analysis (MHA)
to search for mutations that occur frequently with a screening process that requires only a
single step. In the study 162 families with a history of breast and/or ovarian cancers from
various geographic locations were analyzed. Mutations from 35 families were identified, the
majority of which were frame shift mutations resulting from insertions or deletions. Although
the region of BRCA1 analyzed by MHA was only one-quarter of the entire coding sequence,
50% of the mutations that have been reported to date are found in this region. This study also
indicated that specific geographic and ethical origins influence BRCA1 mutations. For
example, an insertion of cytosine at nucleotide 5382 was seen in 9 out of 19 families from
Russia. A deletion of adenine and guanine at nucleotide 185 is a common mutation in the
Ashkenazi Jewish population. MHA is a technique that has a promising future in the
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detection of mutations of the BRCAI gene; however, this procedure is not sensitive enough
to be used for testing on a clinical basis (Gayther et al., 1996).
Miki et al. (1994) speculate that BRCA1 is a tumor suppressor gene, which is a
protein that functions to negatively regulate tumor growth. Familial breast cancer is inherited
as a dominant trait; therefore, it is only necessary to inherit a single copy of a mutant allele
to be genetically predisposed to the disease. In BRCA1 the wild type allele is overcast by a
dominant mutant allele, this disrupts the normal function of BRCA1 as a tumor suppression
gene (Miki et al., 1994).
BRCA1 was found in all breast cell lines which were tested. In normal breast cells
there were no mutations to BRCA1. Chen et al. (1995) located BRCA1 in normal breast cells
primarily in nuclei. In the breast cancer cells BRCA1 was detected primarily in the cytoplasm
and also appears to be completely mislocated in most end-stage breast cancer cells. The
mislocation of BRCA1 suggests that when germ-line mutations alter BRCA1, these
abnormalities help in the initiation and development of breast cancer (Chen et al., 1995).
As previously stated, BRCAI was originally thought to be a tumor suppression gene
(Miki et al., 1994). However, Marx (1997) indicates that new research suggests BRCA1
maybe involved in DNA repair, and any mutations in the gene may disrupt its ability to
function properly.
In 1994 Wooster et al. (1994) performed a study trying to genetically link 15 high-risk
breast cancer families to BRCA1. These families did not show any linkage to chromosome
17q21. Through their research a second "breast cancer susceptibility locus" was discovered.
BRCA2 located on chromosome 13ql2-ql3 indicated a high risk to breast cancer, but not
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ovarian cancer as seen in BRCAI. The BRCA2 gene was mapped using various DNA
markers including D13S260 and D13S263. Using two-point and multipoint lod scores the
BRCA2 gene was narrowed down to the area of DNA marker D 13 S 171 encompassing 600
kb. The cDNA of BRCA2 was analyzed revealing an open reading frame which encodes a
protein consisting of 3418 amino acids and 27 exons (Tavtigian et al., 1996)
In further research Wooster et al. (1995) detected several germ-line mutations in
breast cancer families. These mutations altered the open reading frame of BRCA2, hindering
its suspected function as a tumor suppression gene. In a study conducted by Weber et al.
(1996) various BRCA2 germ-line mutations were identified including a 1 bp deletion in exon
11 at nucleotide 2882, the addition of 9 amino acids, and a "translocation termination at
codon 894". Schubert et al. (1997) suggest that most mutations in BRCA2, which alters its
normal function and cause disease, are a result of premature Stop codons.
As in BRCA1, geographic and ethnic origins influence mutations that are observed.
For example, Thoracius et al. (1996) identified a 5 bp deletion in exon 9 of BRCA2 that has
been seen in 16 families of Icelandic origin. Schubert et al. (1997) report that a deletion of
a tyrosine at nucleotide 6174 is a common mutation among Ashkenazi Jewish families.
Interestingly, unlike BRCA1, there is a relatively high occurance of male breast cancer
associated with BRCA2. In a study conducted by Friedman et al. (1997) male breast cancer
patients were analyzed to see how frequent BRCA1 and BRCA2 germ-line mutations
occurred. The results they obtained indicated no mutations on the BRCA1 gene. There were
2 BRCA2 germ-line mutations that resulted in truncated proteins. Although only 1% of all
breast cancer cases are seen in men, and an even smaller percentage is due to germ-line
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mutations in BRCA2, it is vital to try to resolve the influence of BRCA2 on breast cancer for
both males and females. Interestingly, there was also an "ovarian-cancer cluster" identified
on the BRCA2 gene. In previous reports it has been suggested that BRCA2 does not
influence the onset of ovarian cancer (Friedman et al., 1997).
In BRCA2, as with BRCA1, there are many mutations that have been seen in various
families. The major question is, what is the role of BRCA1 and BRCA2 with relation to
tumor development? Initially, they were put into the category of tumor suppressors, or
gatekeepers (Kinzler and Vogelstein 1997).

Gatekeepers as described by Kinzler and

Vogelstein (1997) are genes which monitor tumor growth by inhibiting growth of the tumor
or promoting death. Inactivation or mutations of these gatekeepers lead to specific cancers,
in this case breast cancer. The other type of gene proposed by Kinzler and Vogelstein (1997)
are caretakers. These genes influence the cell by insuring genetic stability of the cell, making
repairs to DNA. Mutations in the caretakers result in the loss of genetic integrity which leads
to the occurance of tumors. Kinzler and Vogelstein (1997), along with Marx (1997), propose
that BRCA1 and BRCA2 are caretakers whose function is to repair DNA, keeping cell
growth in check. When these caretakers are altered by mutations they can not properly
function. It is proposed that BRCA1 and BRCA2 are caretakers because mutations of these
genes are uncommon in sporadic cases of breast cancer. It is important to determine if
BRCA1 and BRCA2 act as gatekeepers, or the more recently supported function, caretakers,
for practical reasons as well as theoretical ones. If it is determined that BRCA1 and BRCA2
are definitely caretakers, there are additional avenues of treatment that can be pursued
(Kinzler and Vogelstein, 1997). For example, it was determined that BRCA2 genes are
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"sensitive to gamma-irradiation". Thus, patients with BRCA2 mutations could have favorable
results with such treatments (Sharan et al, 1997).
As an interesting side note, BRCA1 has been connected to prostate cancer, a common
form of cancer among men. Langston et al. (1996) assessed the role of BRCA1 germ-line
mutations on the pathology of prostate cancer. BRCA1 was analyzed for germ-line mutations
in a group of men with the disease. One specific mutation, a frame shift mutation in exon 2
resulting in a premature Stop codon in BRCA1, had previously been described and was also
observed in their study.

If this mutation proves to be common among men with a family

history of prostate cancer, a familial connection to the disease may be identified (Langston
et al., 1996). Although the frequency of germ-line mutations in BRCA1 which lead to
prostate cancer is small, the ability to undergo genetic counseling and possibly isolate one's
risk at an early age could aid in the treatment of the disease (Langston et al., 1996).
With the advent of BRCA1 and BRCA2 and their influence on familial breast cancer,
genetic counseling for men and women with a family history of the disease has increased. In
the past, women who had many members of their families diagnosed and eventually die from
breast cancer, considered having full mastectomies although they were not diagnosed with the
disease. Today there is increased technology and genetic counseling techniques to help
people assess their risk and make decisions about their course of treatment (Lyon and
Gorner, 1995). As more and more information about the normal function of BRCA1 and
BRCA2 becomes apparent, scientists will be able to compare this information with what is
known about the function of mutated BRCA1 and BRCA2. Scientists will also be able to
observe what the most common germ-line mutations in BRCA1 and BRCA2 for various
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geographic and ethnic groups are. Also, what effects specific mutations in these genes have
on the initiation and development of breast cancer. In conjunction with continued analysis
of the BRCA1 and BRCA2 genes, genetic counseling techniques will become more refined
to evaluate risk assessment and aid in the early diagnosis of the disease. The ability to assess
one's risk and diagnose the disease in its early stages will facilitate the treatment of some
forms of breast cancer projecting a more successful outcome.
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CHAPTER 4: HUNTINGTON DISEASE
In 1872 George Huntington, a Long Island physician, published a paper, "On Chorea".
In his article Huntington first described the disease we today call Huntington Disease
(Conneally, 1984). Huntington's description of the disease included characteristics such as
a late-onset disorder that didn't afflict patients until mid-life. In his description he also used
such words as "bowing", "twisting" and "grimacing" as he observed patients with the disease
(Lyon and Gomer, 1995). Today, Huntington Disease is described as a progressive disorder
afflicting 5-10 in 100,000 persons. The disease affects motor function, personality and
cognition, eventually resulting in death (Brinkman et al., 1997). From the time of onset of
the disease to death, the average duration of Huntington Disease is 15-20 years (Brinkman
et al., 1997). In general, the first symptoms of Huntington Disease are seen between the third
and fifth decade of life. The symptoms that are associated with Huntington Disease are a
result of premature death of neural cells, primarily in the basal ganglia (Gusella et al., 1983).
Nancy Wexler, a clinical psychologist, and a potential Huntington Disease carrier,
formed the Huntington Disease Collaborative Research Center in 1984, which is a group of
researchers that would work collectively to try to find the genetic cause of Huntington
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Disease. Wexler, whose mother and several other relatives died from Huntington Disease,
was intent on promoting research efforts to find the genetic cause and potential treatment of
Huntington Disease.

Wexler's passion has lead her to organize medical expeditions to

Venezuela every year since 1981. Specifically, three villages in Venezuela were the targets
of the expeditions. San Luis, Barranquitas and Lagueneta have the highest frequency of
Huntington Disease cases in the world. During these expeditions blood samples were taken
from the villagers and a detailed lineage of the disease was formulated. The results that were
obtained linked Huntington Disease back to the early 1800's to a woman appropriately named
Maria Concepcion. The mystery of the origin of Huntington Disease was beginning to
unravel, but the genetic basis of the disease was still not understood (Lyon and Gorner, 1995).
In 1983 Gusella et al. (1983) conducted a study to find a genetic marker associated
with Huntington Disease. Through their research they isolated a 17,000 nucleotide patch of
DNA that could be associated with the gene that results in Huntington Disease (Lyon and
Gorner, 1995). Through further research twelve polymorphic DNA markers were used to
screen for linkage to the Huntington Disease gene. One marker, G8, also referred to as
D4S10, had the highest lod score and corresponded to chromosome 4 (Gusella et al., 1983).
Gusella et al. (1983) then used a technique called in-situ hybridization to isolate the
location of the Huntington Disease gene on chromosome 4. The probe used was the G8
DNA marker which hybridized to the short arm of chromosome 4, narrowing down the
location of the gene. However, this technique was not sensitive enough to indicate the
precise location of the Huntington Disease gene.
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Interestingly, in Gusella et al's. (1983) research blood samples of both American and
Venezuelan kindred were used to isolate the location of the Huntington Disease gene. In both
pedigrees the G8 marker had the highest lod score and hybridized to the short arm of
chromosome 4. This data indicates that the gene responsible for Huntington Disease may be
the same universally with no geographic or ethnic influences (Gusella et al., 1983).
In a study by Wang et al. (1986) a more precise location of the Huntington Disease
locus was reported. In their research in-situ hybridization techniques were also employed.
The results indicate that the Huntington Disease locus lyes within 4pl6.1-4pl6.3 of
chromosome 4 (Wang et al., 1986). In further attempts to narrow down the location of the
Huntington Disease gene, Gilliam et al. (1987) report that by using multipoint analysis
techniques, D4S10 was more refinely mapped to 4pl6.3 of chromosome 4.
Since the first DNA marker corresponding to the Huntington Disease gene was
isolated by Gusella et al. (1983), many other researchers have tried to find additional markers
associated with the gene. Gilliam et al. (1987) identified D4S43, another polymorphic DNA
marker, which could potentially be closer to the Huntington Disease gene than D4S 10. Using
Multipoint analysis the two markers, D4S10 and D4S43, were tested. The results indicate
that D4S43 is closer to the Huntington Disease locus than D4S10O.

This finding was

important and implicated D4S43 as a possible candidate for use in predictive testing assays
(Gilliam et al., 1987).
Research by Robbins et al. (1989) suggests that two more DNA markers that are even
closer to the Huntington Disease gene were discovered. Using somatic hybrid cell mapping
and genetic linkage analysis the two markers, D4S95 and D4S90, were detected on the distal
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portion of chromosome 4 having a close linkage to the Huntington Disease gene. Robbins
et al. (1989) state that the D4S95 marker is the most useful of the two markers and could be
used for predictive testing for Huntington Disease (Robbins et al., 1989).
While other researchers were trying to find the location of the gene responsible for
Huntington Disease, Myers et al. (1985) was trying to identify factors that influence the age
at onset of the disease. In their study, Myers et al. (1985), researched parental factors than
may influence the age at onset. In their report they state that the sex of the affected parent
is a factor that influences the onset of Huntington Disease. They suggest that when the gene
is inherited from the father, the age at onset is earlier than when the gene is inherited from the
mother (Myers et al., 1985).
There was a great deal that was known about Huntington Disease, including factors
influencing age at onset as well as the location of the gene which causes the disorder. It was
now time to try to figure out what mutation(s) influence the expression of the disease.
In 1993 Gusella's lab was working feverishly to clone the 200,000 base pair
Huntington Disease gene in order to find possible mutations.

In February, Marcy

MacDonald, Gusella's senior postdoc, struck gold. MacDonald finally cloned the gene and
had sequenced a portion of it. While analyzing the sequence MacDonald noticed something
unique. There was a sequence of forty eight repeating cytosine-adenine-guanine (CAG)
nucleotide sequences. When compared to the sequence of a normal control, MacDonald
found that the affected population had significantly more trinucleotide repeats compared to
the unaffected controls. Gusella and his colleagues (those that make up the Huntington
Disease Collaborative Research Center) performed numerous assays sequencing the DNA of
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Huntington Disease victims. The results indicated that they all had the same phenomena, a
gene that always began with a long series of CAG repeats (Lyon and Gorner, 1995). It was
as 'simple' as that, a stutter in the gene. Further research indicated that the CAG repeats
found on exon one are found in all individuals, affected and unaffected. The number of CAG
repeats in unaffected individuals range from 6 to 35 with only 1% of unaffected individuals
having between 30 and 35 repeats. In contrast, affected individuals have CAG repeats
ranging from 36 to 121 (Brinkman et al., 1997). In order to identify the number of CAG
repeats an individual has, a technique which uses a Polymerase Chain Reaction (PCR)
protocol was developed. This technique is what is currently used for predictive testing and
diagnosis of Huntington Disease. Interestingly, it has been shown that a significant inverse
relationship has been seen between the number of CAG repeats and the age at onset of
Huntington Disease (Brinkman et al., 1997). In research conducted by Brinkman et al.
(1997), the goal was to estimate one's probability of developing Huntington Disease by a
specific age based on the number of CAG repeats one has. In their study a large number of
individuals with varying numbers of CAG repeats were analyzed. Through their research it
was shown that the number of CAG repeats a person has is the major factor of the age at
onset of Huntington Disease. It was once thought that Huntington Disease was 100%
penetrant, now through their study Brinkman et al. (1997) show that in persons with less than
42 CAG repeats the risk of penetrance is not 100%. Therefore, if a person inherited between
36 and 42 CAG repeats, they may be spared the unforgiving fate of Huntington Disease. In
their study they found that individuals with 50 CAG repeats had a median age at onset of 27,
whereas individuals with 43 CAG repeats had a median age at onset of 44. Brinkman et al.
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(1997) caution against the use of the number of CAG repeats as a predictive tool for age at
onset because it varies from individual to individual.
The CAG repeats produce the amino acid glutamine, the protein which the gene codes
for is called huntingtin. The increased number of CAG repeats results in the formation of
more glutamine, thus an expansion of huntingtin. The discovery of CAG repeats and their
influence on the expression of Huntington Disease has not enabled researchers to understand
what causes the nerve cells of the brain to sicken and ultimately die. Scientists would first
need to understand the normal function of the gene before they could determine how the
mutant gene functions. In a report by Williams (1996) a possible connection was made.
Huntingtin interacts with a protein called glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), which is a key enzyme involved in glycolysis. The theory is that the mutated form
of huntingtin interferes with the normal function of GAPDH and stunts energy production.
It is suggested that since the brain depends predominately on energy produced from the
breakdown of glucose, the disabling of a key component of glycolysis could harm and
eventually destroy nerve cells in the brain by interfering with their source of energy (Williams,
1996).
Scientists now have the ability to provide accurate predictive testing procedures as
well as determine, roughly, the age of onset of Huntington Disease. However, this is all they
know. There is no treatment for Huntington Disease, the biochemical mechanisms that
contribute to the disease are not known. It is an ironic dilemma, to be able to confirm that
someone will someday begin to show the symptoms of Huntington Disease, but to also inform
them that there is nothing that can be done to alter the fate that lies before them.
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Initially, predictive testing was done with polymorphic DNA markers that were
discovered before the gene responsible for Huntington Disease was isolated. There were
certain risks associated with this type of predictive testing. For example, when only one
polymorphic DNA marker, D4S43, was used for testing the results were not very accurate;
whereas, when more polymorphic DNA markers were discovered the predictive test became
more accurate. In one case, a man with a family history of Huntington Disease was tested
when D4S43 was used for predictive testing. The man was told that he had a 17% risk of
inheriting the gene responsible for Huntington Disease. However, when the predictive tests
were improved due to the discovery of more markers, he was retested and told that his risk
for inheriting the Huntington Disease gene was 96%. Although predictive testing is an
effective tool for predicting risk, it may be advantageous to wait until more is known about
the genetic basis of a disease before testing for inheritance. In another case, a woman was
told that she had an 85% risk of inheriting the gene for Huntington Disease. When the gene
for Huntington Disease was isolated she was retested. The test indicated that she had 35
CAG repeats and was told that it was very unlikely that she would develop Huntington
Disease because her CAG repeats were within normal limits (Almqvist et al., 1997).
Another controversy with predictive testing for Huntington Disease is whether
children below the age of 18 should be tested. Bloch and Hayden (1990) state that guidelines
established for predictive testing programs allow only individuals over 18 years of age to be
tested. In the case of Huntington Disease some parents request that their children have
predictive testing done, primarily because of their own curiosity and anxiety. Bloch and
Hayden (1990) argue that children cannot make decisions about predictive testing, and the
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only way it should be done is if it can be demonstrated that it is for the child's benefit.
However, since there is currently no treatment for the prevention of Huntington Disease,
predictive testing for a child would not be for his or her benefit. In contrast, if a child knows
that they will eventually develop Huntington Disease, it may influence their self esteem and
their ability to interact socially and is not at all recommended (Bloch and Hayden, 1990).
Predictive testing is beneficial for individuals who want to know their fate for personal
reasons. For example, it may influence a couples decision on whether or not to have children.
Although there isno treatment for Huntington Disease, the information that has been
discovered in recent years is very encouraging. With the continuation of research for this
disease, hopefully someday there will be a course of action that scientists and physicians can
take to combat Huntington Disease.
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CHAPTER 5: SCHIZOPHRENIA
Schizophrenia is a disease which affects approximately 1% of the population of the
United States. Symptoms of the disease include hallucinations, paranoia, delusions, disrupted
thought processes and frequent inability to control emotions. It is thought that several factors
influence the onset of the disease, including inheritance and environmental factors (Pulver et
al. 1994).
The strongest evidence that schizophrenia is indeed inherited comes from adoption
and twin studies. In studies involving schizophrenics that were adopted into families from the
general population, it has been shown that the adopted children develop schizophrenia even
though they are not raised by schizophrenic families. In twin studies, monozygotic twins
showed a higher concordance, having both been diagnosed with schizophrenia, than dizygotic
twins. These twin and adoption studies support the hypothesis that schizophrenia is heritable
(Carlson, 1991).
Although it is thought that genetic factors are involved in the pathogenesis of
schizophrenia, it is not clear how it is inherited. There has been extensive research to try to
find a locus for schizophrenia; however, there are many variables that make this difficult.
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Primarily it is hard to develop family lineage for the disease, because in many cases
schizophrenics do not reproduce. Schizophrenics are also less likely to volunteer to be part
of a study about the disease. There is also a lack of understanding of the genetic mechanism
that results in biochemical changes associated with schizophrenia. A great deal of research
has been conducted to try to find potential chromosomal linkage to schizophrenia and develop
a better understanding of its inheritance (Pulver et al., 1994).
In a study by Pulver et al (1994) analysis of 39 families, all diagnosed with
schizophrenia based on criteria in the Diagnostic and Statistical Manual of Mental Disorders
(DSM-III-R), was conducted. In the study 240 polymorphic DNA markers that are randomly
distributed over the genome were used to identify potential linkage to schizophrenia. Two
markers gave the highest lod scores, D22S268 and D22S307 spanned approximately 23 centiMorgans (cM) from 22q 12-q 13.1. This data seemed very promising, but in order to obtain
more concrete results the study needed to be replicated. Pulver et al. (1994) conducted a
follow-up study to try to replicate linkage of schizophrenia to chromosome 22q 12-q 13.1. In
this study 217 families from various geographic locations were analyzed. Again, all subjects
in the study met DSM-III-R criteria for schizophrenia.

Likelihood of linkage of two

polymorphic DNA markers, D22S268 and D22S307, was based on results of linkage analysis
of chromosome 22. The results of this study indicated that there was no linkage of these
markers to chromosome 22ql2-ql3.1 for the 217 families. These results do not support the
initial research of Pulver et al. (1994) that suggested possible linkage of schizophrenia to
chromosome 22q12-q13. 1 (Pulver et al., 1994).
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In further research conducted by Coon et al (1994) linkage analysis using 329
polymorphic DNA markers was conducted. In this research 9 families were analyzed, the
linkage analysis revealed high lod scores for markers associated with chromosome 4, D4S35;
chromosome 14, D14S17; chromosome 15, D15S1; and chromosome 22, D22S84 and
D22S55. According to Conn et al. (1994) the regions that have been identified in this study
are worthy of additional research to try to isolate a specific schizophrenia locus. Coon et al.
(1994) also suggest that there may be several genes that interact and are collectively
responsible for the onset of schizophrenia.
Although the chromosomal location which causes, or triggers, the onset of
schizophrenia is not known, researchers have an understanding of how schizophrenia
functions neurologically. An initial hypothesis suggested that schizophrenia is a result of
overactive dopaminergic synapses, suggesting that schizophrenics have an abnormal amount
of dopamine, a neurotransmitter, in their brain. However, new research by Moghaddam and
Adams (1998) reports that there is evidence that the onset and progression of schizophrenia
is due to glutamatergic mechanisms. In schizophrenics there is a higher than normal level of
glutamate, another neurotransmitter. If the higher than normal glutamate levels can be
reduced and controlled, there may be positive behavioral changes. Currently, neuroleptics,
which is medication given to schizophrenics, function by disabling the action of dopamine.
This treatment does help to reduce such symptoms as paranoia and hallucinations; however,
it does not give much relief to other symptoms of the disease including cognitive and
emotional instability (Wickelgren, 1998). In Moghaddam and Adams' (1998) study, a new
drug, LY354740, was used in rodent trials to see if it influenced the symptoms of
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schizophrenia in rats. LY354740 functions by stimulating a "subgroup of metabotropic
glutamate receptors" which act to regulate glutamate levels. In rodent trials it has been
observed that LY354740 regulates the output of glutamate when levels of the
neurotransmitter become to high; however, LY354740 does not influence glutamate receptors
when levels of the neurotransmitter are normal. In the rodent experiments, phencyclidine
(PCP), a psychoactive drug which "induces schizophrenic-like symptoms" and causes an
increase in levels of glutamate transmission, was administered to control and experimental
rats. In the control group the PCP caused glutamate levels to rise and rats developed
symptoms of schizophrenia; frantic running, incessant head twisting and jerking. In the
experimental group LY354740 was administered as well as PCP. In this group there was no
elevation of glutamate and there were no signs of schizophrenic behavior. The experimental
group was also able to successfully navigate mazes and showed the same cognitive ability as
the normal group of rats. In rodent trials LY354740 appears to be very promising, but many
drugs that are effective in animal trials fail in human trials. In order to see if LY354740 is
effective in humans, it needs to undergo testing on schizophrenia patients (Moghaddam and
Adams, 1998).
Although the genetic basis of schizophrenia in not yet understood, new approaches
to treat the disease appear to have a promising future. If schizophrenia patients can get relief
from the unforgiving symptoms of schizophrenia, it would be a milestone in the treatment of
the disease.
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CONCLUSION
Identifying genes that are responsible for the onset of particular diseases is an
overwhelming accomplishment. However, as the technology for identifying genes improves,
so does the potential for genetic discrimination. When James Watson announced the plans
to sequence the Human Genome, he allocated funds to research the Ethical, Legal and Social
Implications (ELSI) of the project. The ELSI work group was developed and is responsible
for evaluating issues that are associated with the project, such as privacy, genetic
discrimination, and health care. In an article by Hudson et al (1995) the issue of genetic
discrimination involving health care was discussed. In some cases patients were denied health
coverage based on their genetic susceptibility to a particular disease. It is frightening for
people to consider loosing their health coverage based on their genetic predisposition. In
some instances patients undergo genetic testing secretively, so that their insurance carriers
will not find out. In some states laws have been passed which protect individuals from being
denied health insurance based on genetic information; however, such laws need to exist
throughout the nation (Hudson et al., 1995). Interestingly, it has been recommended that
laws be implicated to prevent positive discrimination. This would discourage insurance
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companies from giving low risk clients lower insurance rates.

This type of positive

discrimination could lead to a societal division of those with "good" DNA versus those with
"bad" DNA (Doby, 1995). Genetic discrimination is not limited to the health care industry;
it could venture into many areas of society such as the work place and schools. Nancy
Wexler, the leader of the ELSI work group, states that "Genetic information itself is not going
to hurt the public, what could hurt the public is existing social structures, policies and
prejudices." (Lyon and Gorner, 1995). Ours is a society where discrimination and breach of
privacy issues seem to be the norm, rather than the exception. That is why it is imperative
that as new discoveries are made to advance the Human Genome Project, the ELSI work
group stays in stride to keep the project in check, strengthening its moral backbone.
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